REFLECT Study Confirms Efficacy Of GenSight's Gene Therapy Lumevoq

French biotech GenSight Biologics reports top-line results from the Phase III REFLECT study, backing the efficacy of its lead gene therapy in a devastating eye disease, and prepares plans to commercialize the product.